Truist Securities Maintains Buy on Astrana Health, Raises Price Target to $55
Truist Securities analyst Jailendra Singh maintains Astrana Health (NASDAQ:ASTH) with a Buy and raises the price target from $47 to $55.
Read original at benzingaStocks · News reference
Astrana Health Sees Q3 Sales $1.000B-$1.030B vs $1.021B Est
Astrana Health (NASDAQ:ASTH) sees Q3 sales of $1.000 billion-$1.030 billion vs $1.021 billion analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:26 PM
- Checked
- Aug 6, 2026, 8:26 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Barclays Maintains Overweight on Astrana Health, Raises Price Target to $53
Barclays analyst Andrew Mok maintains Astrana Health (NASDAQ:ASTH) with a Overweight and raises the price target from $50 to $53.
Read original at benzingaAstrana Health Affirms FY2026 Sales Guidance of $3.800B-$4.100B vs $4.001B Est
Astrana Health (NASDAQ:ASTH) affirms FY2026 sales outlook from $3.800 billion-$4.100 billion to $3.800 billion-$4.100 billion vs $4.001 billion estimate.
Read original at benzinga